Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q3 FY24
Glenmark's Q3 FY24 consolidated revenue fell 16% YoY to INR 29,096 million, primarily due to a one-time India distribution restructuring that reduced channel inventory.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q3 FY24 consolidated revenue fell 16% YoY to INR 29,096 million, primarily due to a one-time India distribution restructuring that reduced channel inventory. Excluding this, revenue would have grown ~9%. The India business reported primary sales of INR 2,622 million, but secondary sales grew 12%, outperforming the market. North America declined 9% to $91.6 million due to lack of new launches, while Europe grew 29% and ROW 10.8%. Management guided for a significant EBITDA margin improvement in FY25 driven by R&D cost savings of $30-35 million from the IGI alliance, Ryaltris scaling to ~$80 million in sales, and operating leverage. Key risks include execution on the Monroe facility ramp-up and U.S. respiratory launches.
ग्लेनमार्क की तीसरी तिमाही में कुल कमाई 16% घटकर 2,909 करोड़ रुपये रही। इसकी मुख्य वजह भारत में बिक्री के तरीके में एक बार का बदलाव था, जिससे दुकानों पर माल कम रह गया। अगर यह बदलाव न होता, तो कमाई 9% बढ़ती। भारत में प्राथमिक बिक्री 262 करोड़ रुपये रही, लेकिन दुकानों से असली बिक्री 12% बढ़ी, जो बाजार से बेहतर है। उत्तरी अमेरिका में नए उत्पादों की कमी से बिक्री 9% गिरी, जबकि यूरोप में 29% और बाकी दुनिया में 10.8% बढ़ोतरी हुई। कंपनी का कहना है कि अगले साल मुनाफा काफी बढ़ेगा, क्योंकि रिसर्च पर खर्च कम होगा और नई दवा रायल्टी की बिक्री 80 करोड़ डॉलर तक पहुंचेगी।
Promises0 met · 1 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Monroe facility ramp-up delays
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India secondary sales growth (IQVIA)
12%
+4pp vs market growth of 8%
India secondary sales grew 12% in Q3, outperforming the overall market growth of 8%.
Ryaltris FY25 sales guidance
$80M
N/A (forward guidance)
Management expects Ryaltris sales to reach ~$80 million in FY25, with high margins.
R&D spend reduction from IGI
$30M-$35M
N/A (forward guidance)
IGI alliance expected to reduce annual R&D spend from $75-80M to $45-50M, saving $30-35M.
Working capital improvement from India restructuring
INR 530 Cr
N/A (one-time)
India distribution restructuring improved working capital by ~INR 530 crore.
What Changed vs Last Quarter
NEW
India business to return to ~INR 1,000 crore quarterly run rate in Q4
After the one-time restructuring, India primary sales will normalize to ~INR 1,000 crore per quarter, growing 10-12% YoY.
NEW
Ryaltris FY25 sales of ~$80 million
Management expects Ryaltris to generate ~$80 million in booked sales in FY25, with high margins.
NEW
R&D spend to reduce by $30-35 million in FY25
IGI alliance will lower annual R&D spend from $75-80 million to $45-50 million, boosting EBITDA.
NEW
Net cash positive by end of FY24
Proceeds from GLS divestment (~INR 5,000 crore net) will make the company net cash positive by March 2024.
DROPPED
Core EBITDA margin target of ~19% by FY25
Management expects core EBITDA margins to reach ~19% in FY25, driven by 2% improvement from lower R&D spend and additional operating leverage from Europe and LatAm.
DROPPED
India business to grow 12-15% over next 3 years
India formulation business expected to grow at 12-15% CAGR over the next three years, supported by Rx, OTC, and institutional segments.
DROPPED
Europe business to grow 15-20% minimum
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
DROPPED
Fluticasone MDI filing by Q4 FY24/Q1 FY25
Glenmark expects to file the fluticasone MDI (generic Flonase) in the US by end of FY24 or early FY25.
NEW RISK
Monroe facility ramp-up delays
Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.
NEW RISK
U.S. respiratory launch timeline uncertainty
Generic Flovent pMDI NDA filing expected in Q1 FY25, but approval and launch timing remain uncertain, affecting U.S. growth trajectory.
NEW RISK
India business recovery may be slower than guided
Despite guidance of INR 1,000 crore quarterly run rate, the one-time restructuring impact may have lingering effects on channel dynamics.
RISK GONE
US business uncertainty and pricing erosion
US business remains a big unknown due to pricing erosion (~5% mid-single digit) and supply disruptions; management struggles to provide specific guidance.
RISK GONE
Monroe facility reinspection timeline uncertain
Monroe facility remediation is largely complete, but FDA reinspection timeline is unpredictable, delaying potential revenue from the plant.
RISK GONE
GLS divestment execution risk
The GLS divestment to Nirma is subject to regulatory and shareholder approvals; any delay could impact FY25 margin and PAT improvement plans.
RISK GONE
India acute segment slowdown may persist
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
Mentioned in Q1 FY24, Q2 FY24
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.
Fast read
Guidance and risk preview
After the one-time restructuring, India primary sales will normalize to ~INR 1,000 crore per quarter, growing 10-12% YoY.
Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.
View Risks →